Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
| Заболевание | Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma |
|---|---|
| Фаза | Фаза 2 |
| Спонсор | HonorHealth Research Institute |
| Статус | Завершено |
| Участники | 19 участн. |
| Вмешательство | Paclitaxel protein bound, Gemcitabine, Cisplatin, Hydroxychloroquine |
| Дата начала | 1.12.2020 |
| Дата завершения | 21.02.2024 |
| Публикация результатов | 21.07.2026 |
Кратко
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
CA 19-9 Normalization
| Treatment | 9.1 Percentage of participants |
|---|---|
| Treatment | 18.2 Percentage of participants |
| Treatment | 72.7 Percentage of participants |
| Treatment | 36.4 Percentage of participants |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group